LIVESTREAM: Thoracic Oncology 2019 - Watch LIVE and On-demand Watch LIVE Register Here »
Thoracic Oncology 2019
Cart 0

iStock-961295726.jpg
 

* NEW LIVESTREAM SERVICE AVAILABLE

Watch LIVE and ON-DEMAND from London on November 28-29th

Thoracic Oncology 2019 focuses on the future of integrated practice for non-small cell lung cancer. We are delighted to announce that the conference will be Live Streamed to a worldwide audience on Thursday 28th and Friday 29th November. Join a superb international faculty delivering short presentations with interactive audience participation LIVE from your home or office.


Watch #ThoracicOncology19 LIVE and on-demand

  • Watch anytime, from anywhere.
  • Soak in the knowledge & learn from our expert panel of speakers
  • Watch recorded sessions at a time more convenient to you via our video on demand archive.
  • You will have access to the 'video on demand' archive for 12 months of further study

We know by filming the conference it will provide inspiration & education to those that can't travel, or can't attend. Don't miss out, our LIVE & on-demand coverage is the next best thing to being there.

How to register:

Simply register below and we'll send you unique login details for conference. Recorded presentations will remain online for 12+ months access.

Who is speaking?

This two day conference will feature over 30 international speakers - see the agenda below for more information

 

Day 1 : Watch LIVE on Thursday 28 November

 
 

Future of early disease identification

The results of NELSON reinforce the importance and value of lung cancer screening. As screening programmes become more widely implemented, new challenges emerge on recognising when CT appearances are benign, when and how to obtain confirmatory tissue diagnosis.

Harry de Koning - Erasmus MC, Netherlands

Following from the announcement of the results of NELSON at the Presidential session of the IASLC 2018 World Conference of Lung Cancer, Professor Harry De Koning will be presenting the implications of NELSON to inform us on results and residual uncertainties for lung screening.

Anand Deveraj - Royal Brompton Hospital, London

Dr Anand Deveraj, a thoracic radiologist that reported and advised on the UK lung cancer screening programme will discuss radiological diagnosis in the era of artificial intelligence and machine learning,

Simon Padley - Royal Brompton Hospital, London

Professor Simon Padley, thoracic radiologist will be presenting the advances in pre-operative biopsy localisation techniques and discuss the merits of pre-theatre localisation versus on-site radiologist (hybrid) theatre presence.

Calvin Ng - Prince of Wales Hospital, Hong Kong

The hybrid theatre re-sets the rules, choices and options for pre-operative localisation and Associate Professor Calvin Ng, will be presenting on the equipment, utility and rationale as surgeon within a hybrid theatre.

Audience discussion and questions:

What is the optimum patient pathways for pre-surgical diagnosis?

Is there any international consensus on best follow up strategies for lung screening?

 

Future of locally ablative treatments I

session chair - Peter Goldstraw, Royal Brompton Hospital, London

The screen detected ground glass opacity and / or lesions that have a low or uncertain malignant potential remain a challenge in surgical management. LCSG 832 have advocated lobectomy as the treatment of choice, but changing histological epidemiology and better understanding of the different malignant potential of adenocarcinoma questions the applicability of LSCG 832 in today’s practice.

Paul Van Schil - University Hospital of Antwerp, BELGIUM

Professor Van Schil was a co-author on the IASLC recommendations for T category coding for sub-solid nodules and will lead the presentation on this session that focuses on the management of sub-solid lesions that are less than 3cm in size. The presentation will discuss the “new” IASLC adenocarcinoma and the relevance with respect to screen and incidentally detected cancers.

Dominique Gossot - Institut du Thorax Curie-Montsouris, Paris

Following on from his successful conference on sub-lobar resections in Paris, Professor Gossot will be discussing the arguments of surveillance versus resection for the management of ground glass lesions less than 3cm.

Hisao Asamura - Keio University School of Medicine, Tokyo

Professor Hisao Asamura is the current TNM 9 staging chair for lung cancer and the Chief Investigator for JCOG 0802. His talk will focus on the rationale of sub-lobar resection in JCOG 0802 and compare the differences in the trial design with the US Alliance of Oncology Trials (formerly CALGB) of segmentectomy versus segmentectomy or wedge resection and prevailing views on the benefits of “anatomic” sub-lobar resection.

Audience discussions and questions:

How can we put patients views in the management pathway for screen detected ground glass lesions?

Do western guidelines also apply to countries like China and Japan where non-smoking lung cancer incidence is high?

 

Future of locally ablative treatments II

session chair - Dr Alessandro Brunelli - Leeds teaching hosptials, leeds

Optimum access (single, multiple keyhole, thoracotomy) and choice of surgical adjuncts (robotics) remain heatedly debated in the surgical arena. This session focus on the emerging developments in single incision surgery and robotics with a debate on where and how experts see the technology developing with respect to number of incisions and accompanying cost of surgical adjuncts.

Joel Dunning - South Tees Hospital, Middlesborough

Mr Joel Dunning is best known for his travels to discover new and emerging operative techniques. As an investigator for the UK VIOLET (VATS versus open surgery) trial, surgical innovator (micro-lobectomy) and robotic surgeon will be presenting a state of art on surgical technology.

Alan Sihoe - The University of Hong Kong Shenzhen Hospital, Hong Kong

Associate Professor Alan Sihoe is an established single port surgeon who writes and lectures internationally on the topic will be presenting an overview of the development of single incision surgery (uniportal and sub-xiphoid) and his views on the future of this technique.

Giulia Veronese - Humanitas Research Hospital, Milan

Dr Giulia Veronese, an experienced robotic thoracic surgeon and Chief Investigator of the ROMAN trial (robotic versus vats surgery) will be presenting her views on the role of robotic surgery for lung cancer in comparison to conventional VATS surgery.

Audience discussions and questions:

Why is the balance changing from less incisions, cheaper surgical adjuncts (VATS) to more incisions and expense with robotics?

 

Future of locally ablative treatments III

Stereotactic ablative body radiotherapy (SABR) is gaining widespread acceptance as a local option for the management of local disease, and the only RCTs to date demonstrate superior efficacy in the elective setting. SABR versus surgery trials have been notoriously difficult to recruit to and in this session, Chief investigators debate the utility of SABR for the primary treatment options for low and high risk patients.

kevin franks - consultant Clinical Oncologist, Leeds Teaching Hospitals NHS Trust

Associate Professor Kevin Franks the Chief Investigator of UK SABRTooth Trial will present an overview of SABR versus surgery trials and discuss the difficulties in the recruitment.

Suresh Senan - Amsterdam University Medical Center, Amsterdam

Professor Suresh Senan, a radiation oncologist, Chief Investigator of ROSEL (SABR versus surgery trial) published jointly with STARS in the Lancet, demonstrating superior survival with SABR compared to surgery for early non-small cell lung cancer. Professor Senan will discuss the role of SABR for elective low-risk patients with lung cancer.

HIRAN C FERNANDO - INOVA FAIRFAX MEDICAL CAMPUS, VIRGINIA COMMONWEALTH UNIVERSITY, VIRGINIA

Professor Hiran Fernando is the Chief Investigator for STABLEMATES (SABR versus surgery), a randomized trial comparing the utility for "high risk" patients with non-small cell lung cancer. He will provide insights on how recruitment is undertaken in the US and the rationale for the approach in the high risk cohort.

Audience discussions and questions:

Why isn’t SABR recommended as first line treatment option in guidelines for early non-small cell lung cancer patients in low risk patients?

 

Future of locally ablative treatments IV

New technologies are emerging in this space for locally ablative treatments. This sessions provides an overview of what is currently in development with a view to clinical application.

Corinne Faivre-Finn - Christie Hospital, Manchester

The Christie Hospital in Manchester is one of the few sites for the provision for MR Linac and proton beam therapies. Professor Corinne Faivre-Finn will be presenting an overview of the new technology and discuss the implementation plans (clinical and research) within the UK and internationally.

Calvin Ng - Prince of Wales Hospital, Hong Kong

Associate Professor Calvin Ng, thoracic surgeon will present the application of electromagnetic navigation bronchoscopy and local ablation of central tumours and future clinical utility of this technology.

Simon Padley - Royal Brompton Hospital, London

Professor Simon Padley, thoracic radiologist will present advances in radiofrequency ablation and discuss it’s place in the management pathway for early local disease.

Audience discussions and questions:

Do we always need tissue diagnosis prior to local ablation?

Currently local ablation treatment options are unique to the interest and development in each site, which technology should we all be looking to acquire?

 
 

Day 2 : Watch LIVE on Friday 29 November

 
 

Integrated care of early stage NSCLC (part I)

It’s no longer a question of surgery for early stage non-small cell lung cancer. Today, we work towards full integration of management options in order to optimise survival at all stages of lung cancer and in some cases to achieve cure.

David Gilligan - Addenbrookes Hospital, Cambridge

Professor David Gillian, Chief Investigator of the UK MRC LU22 trial (pre-operative chemotherapy) opens today’s session on the place of neo-adjuvant and adjuvant chemotherapy for patients undergoing surgery in the era of immno-oncology.

CECILE Le Pechoux - Institut Gustave Roussy, Paris

Chief Investigator of EORTC LungART and radiation oncologist Professor Cecile Le Pechoux discusses the rationale behind post-operative radiotherapy for patients with N2 disease, and it’s role in the tri-modality treatment pathway.

Audience discussion and questions:

What is the best position of radiotherapy in the treatment pathways, with known N2 (before surgery) and incidental N2 (after surgery)?

 

Integrated care of early stage NSCLC (part II)

Wu Yi Long - Guangdong General Hospital, Guang Zhou

Chief investigator of the chinese ADJUVANT trial, Professor Wu Yi Long, a thoracic surgeon will be discussing results of adjuvant EGFR TKI trials in the post-RADIANT setting where discordant results on survival have been reported.

Mary O'Brien - Royal Marsden Hospital, London

Professor Mary O’Brien Chief Investigator of EORTC PEARLS (adjuvant pembrolizumab) will be discussing the rationale of post-operative adjuvant immunotherapy and outlining the current clinical trials evaluating this question.

Valerie Rusch - Memorial Sloan Kettering Cancer Center, New York

Professor Valerie Rusch, Chief investigator of the LCMC3 (neo-adjuvant atezolizumab), Investigator for NA_00092076 (neoadjuvant pembrolizumab) will be discussing the rationale of neo-adjuvant immunotherapy and outlining the current clinical trials evaluating this question.

Enriqueta Felip - Vall d'Hebron Institute of Oncology, Barcelona

A provocative title of a talk was given to Professor Enriqueta Felip, a medical oncologist - with the advancements of immunotherapy, does this treatment have the potential to be the primary treatment for early stage non-small cell lung cancer?

Audience discussion and questions:

What is the criteria for adjuvant treatment in stage IB?

 

Integrated care of stage III NSCLC

The first generation of clinical trials in IIIA N2 disease did not have a clear definition of resectable IIIA N2 disease and the PACIFIC trial now divides our clinical management by surgical resectability (but without a clear distinction). This session aims to define where the role of chemo-radiotherapy and surgery now sits in the patient pathway with a working definition “resectable” IIIA N2 disease and where immunotherapy (with chemotherapy and with radiotherapy) features in the management of “unresectable” disease.

Eric Lim - Royal Brompton Hospital, London

Professor Eric Lim, is a thoracic surgeon who has lectured widely on this topic, he Chaired the British Guidelines on Radical Management of Lung Cancer advocating patient choice for surgery versus radiotherapy for local control in conjunction with chemotherapy. He will be discussing the concepts of “resectability” in the PACIFIC era.

Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf

Professor Martin Reck, a medical oncologist and PACIFIC trial investigator, will be presenting the role of immunotherapy in “unresectable” stage III disease and where it fits in the patient pathway.

Corinne Faivre-Finn - Christie Hospital, Manchester

Professor Faivre-Finn is a radiation oncologist and PACIFIC trial investigator, will be discussing the role of radiotherapy in “unresectable” stage III disease.

Audience discussion and questions:

What determines if a stage III cancer is “resectable”?

 

Integrated care of advanced NSCLC

With simultaneous pushing of the boundaries between molecular targeted treatments and immunotherapy, options are increasing for patients with advanced disease, this session provides an overview of the current evidence and insights into future development of treatment strategies.

Tony Mok - Chinese University of Hong Kong, Hong Kong

Professor Tony Mok is a leading medical oncologist in the field of molecular targeted therapy, Chief Investigator of iPASS will be discussing the role of targeted molecular treatments in the era of immuno-oncology.

Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf

Professor Martin Reck, medical oncologist and Chief Investigator of KEYNOTE 24 will be presenting an overview on immunotherapy for advanced disease.

Enriqueta Felip - all d'Hebron Institute of Oncology, Barcelona

Professor Enriqueta Felip, medical oncologist and investigator on KEYNOTE 189 (pembrolizumab plus chemotherapy) reporting synergistic effect in improving lung cancer survival will be presenting her views in this rapidly advancing field for non-squamous and squamous lung cancer (KEYNOTE 407).

Audience discussion and questions:

In patients with actionable targets and high PD-L1 expression, what is the correct sequence of treatment?

What is the optimum duration of IO treatment?

What is the role of molecular testing/screening for RET fusions?

 

Integrated care of “oligometastatic” NSCLC

With continuing research advances, clinicians are now tackling more advanced stages of lung cancer. Interest in the field of radical management of metastatic disease is commencing in patients with low tumour burden. This session explores integrated care of advanced disease using immunotherapy as a standard of care augmented by different forms of local consolidation therapy.

Suresh Senan - Amsterdam University Medical Center, Amsterdam

Professor Suresh Senanm radiation oncologist will be discussing the role of radiotherapy (with chemotherapy), available evidence and the trials of radiotherapy in the management of oligometastatic disease.

David Palma - London Health Sciences Centre, Ontario

Dr David Palma, radiation oncologist will be presenting his views on the development of radiotherapy in conjunction with immunotherapy for the management of “oligometastatic” non-small cell lung cancer.

Eric Lim - Royal Brompton Hospital, London

Professor Eric Lim, thoracic surgeon will be discussing the research in surgery for oligometastatic disease that is integrated in today’s standard care of immunotherapy.

Audience discussion and questions:

Is there a working definition of what is a patient with oligometastatic disease?

 

Novel approaches to advanced disease

Research in the field of lung cancer has lead to blockbuster discoveries in the last 10 years, ongoing new and developmental implementation and research strategies are still underway. This session explores the role of population based implementation of targeted treatments and showcases the work of leading researchers in the development of new immunotherapeutic approaches.

Sanjay Popat - Royal Marsden Hospital, London

Dr Sanjay Popat, medical oncologist and UK lead for MATRIX will be discussing the possibilities and challenges of implementing a population based approach for personalised molecular targeted therapy.

Alastair Greystoke - Newcastle University, Newcastle upon Tyne

Dr Alastair Greystoke, medical oncologist will be discussing adoptive T cell therapy for lung cancer.

Sergio Quezada - University College London, London

Professor Sergio Quezada, lead immunologist for TracerX will be discussing new immunotherapeutic approaches for lung cancer.

About the Conference

Treatment regimens in non-small cell lung cancer are no longer neatly divided into surgery for early disease and chemo-radiotherapy for advanced disease. We are in an era of cross speciality integration in all disease stages of lung cancer. Thoracic Oncology 2019 focuses on the transition from current to future practice with a superb international faculty delivering short presentations accompanied by an interactive audience participation in discussions, questions and answers.

It’s your opportunity to interact with the experts to determine their views on the future landscape for the management in thoracic oncology, in a conference is designed to target surgeons, oncologists, chest physicians, the wider multi-disciplinary team including trainees in the management of lung cancer.

It’s a great honour and privilege for me to invite you to join us in London on the 28 and 29 November 2019!

Professor Eric Lim

Royal Brompton Hospital, London, United Kingdom

How to register for the Live Stream & Video On-Demand Archive

Simply register below and we'll send you unique login details for conference. Recorded presentations will remain online for 12+ months access.


FAQ - Frequently Asked Questions

Q. What sessions are being recorded and streamed?
We're live streaming every session in the main auditorium and recording all keynote presentations.

Q. How long will video recordings be made available for?
Videos will be made available for viewing all year round. Our aim is to inspire and educate as many viewers as possible.

Q. When will recorded sessions be made available?
We have dedicated video editors on-site, who will be busy editing and uploading presentations as soon as each session ends.

Q. Due to timezone differences/work commitments I won't be able to watch live. Is there a catch-up service?
Yes - as soon as each session is finished the edit process begins. Videos will be made available within 6-12hrs of each session ending (the quicker the better). You will receive email updates when new content is added to the video on-demand archive.

Q. Who is speaking, and where can I view the program?
View the programme here

Q. Is it possible to test the live stream in advance of conference?
Yes - we'll run a test stream from the venue before the event starts - you'll be invited to join the stream from 8:45AM. We will go live 1hr before conference to test audio and video. Our dedicated support team will also be available via support@switchenwmedia.com if you have any technical queries.


Q. Do you have an example video? will there me multiple cameras?
Yes - we have a professional multi-camera film crew producing the event - here's an example, filmed at a VATS symposium



Q. Is there still time to register and attend the conference in London?

You can register to attend the event in person at the Millennium Gloucester Hotel, London - visit our delegate registration page for more info + quote discount code CTSNET for a 10% Discount in person, in London


Endorsed by:

Limited tickets sponsor:

Supported by:

IASLC-Logos-HZ-tag (2).png
medela-logo-vector.png
AME logo.jpg

main sponsors:

Arthrex.png
astrazeneca.png
Medtronic.png
Ethicon_RGB.jpg
 

28-29 November 2019

Millennium Gloucester Hotel, London, united kingdom

Picture1.jpg

Royal College of Physicians London approved 11 continuing professional development (CPD) points.

Blank.jpg
 

conference Venue

Millennium Gloucester Hotel

4 Harrington Gardens

London SW7 4LH

 

Dates

Thu 28 November 2019 (11:00 am to 5:20 pm)

Fri 29 November 2019 (9:00 am to 4:30 pm)